Skip to main content

Table 2 Dysregulated miRNAs and their involvement in liver disease. ICC intrahepatic cholangiocarcinoma, HNSCC head and neck squamous cell carcinoma

From: MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice

MicroRNA

Liver disease

Target gene(s)

miR-155

Protective role against non alcoholic steatosis [33]

LXR-α[33] C/EBPβ, FOXP3 [35–37]

Up-regulated in NASH [34]

Up-regulated in HCC [35]

MiR-155 deficiency attenuates steatosis and fibrosis [36]

miR-193b

Down-regulated in HBV+ HCC [43]

CCND1, ETS1 [43]

NF1 (HNSCC) [46]

Smad3 (glioma) [47]

miR-20a

Down-regulated in HCC [49]

Mcl-1 [49]

miR-200a

Up-regulated in NAFLD [51]

ZEB1, ZEB2 [54]

Down-regulated in HCC [52]

miR-200c

Up-regulated in NAFLD [51]

ZEB1, ZEB2, NCAM1 [54]

Down-regulated in HCC and ICC [54]

miR-27a

Up-regulated in HBV+ HCC [55]

RXRα, PPARα/γ, FASN, SREBP1, SREBP2 [58, 59]

miR-31

Up-regulated in fibrosis [60]

FIH1 [60]

Up-regulated in HCC [17, 53]

miR-93

Up-regulated in HCC [61, 62]

PTEN, CDKN1A [62]

miR-99b

Up-regulated in HCC [69]

mTOR (pancreatic cancer) [66]

CLDN11 [69]

miR-125a-5p

Down-regulated in HCC [89]

SIRT7 [89]

Biomarker in liver disease [93]

miR-182

Up-regulated in NAFLD-fibrosis [98]

FOXO3 [98]

MTSS1 [94], Cebpa [95],

Up-regulated in HCC [94–97]

EphrinA5 [96], FOXO1 [97]